Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma | Zendy

Steven O’Day | Zendy; Alexander M.M. Eggermont | Zendy; Vanna ChiarionSileni | Zendy; Richard Kefford | Zendy; JeanJacques Grob | Zendy; Laurent Mortier | Zendy; Caroline Robert | Zendy; Jacob Schachter | Zendy; Alessandro Testori | Zendy; Jacek Mackiewicz | Zendy; Philip Friedlander | Zendy; Claus Garbe | Zendy; Selma Ugurel | Zendy; Frances A. Collichio | Zendy; Wei Guo | Zendy; Joelle Lufkin | Zendy; Safi R. Bahcall | Zendy; Vojo Vukovic | Zendy; Axel Hauschild | Zendy

Open Access

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

Author(s) -

Steven O’Day,

Alexander M.M. Eggermont,

Vanna ChiarionSileni,

Richard Kefford,

JeanJacques Grob,

Laurent Mortier,

Caroline Robert,

Jacob Schachter,

Alessandro Testori,

Jacek Mackiewicz,

Philip Friedlander,

Claus Garbe,

Selma Ugurel,

Frances A. Collichio,

Wei Guo,

Joelle Lufkin,

Safi R. Bahcall,

Vojo Vukovic,

Axel Hauschild

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.44.5585

Subject(s) - medicine , paclitaxel , hazard ratio , oncology , tolerability , clinical endpoint , chemotherapy , proportional hazards model , randomized controlled trial , adverse effect , confidence interval

Elesclomol, an investigational first-in-class compound, induces oxidative stress, triggers mitochondrial-induced apoptosis in cancer cells, and shows synergy with taxanes in tumor models. Following completion of a phase II trial of elesclomol in combination with paclitaxel that met its primary end point of progression-free survival (PFS), this randomized, double-blind, controlled phase III study was conducted to confirm the efficacy and tolerability of elesclomol in combination with paclitaxel versus paclitaxel alone in patients with advanced melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research